D. P. Tabassum, K. Polyak, and . Tumorigenesis, It takes a village, Nat. Rev. Cancer, vol.15, pp.473-483, 2015.

D. P. Tabassum and K. Polyak, Tumorigenesis: It takes a village, Nat. Rev. Cancer, vol.15, pp.473-483, 2015.

I. Dagogo-jack and A. T. Shaw, Tumour heterogeneity and resistance to cancer therapies, Nat. Rev. Clin. Oncol, vol.15, pp.81-94, 2018.

P. Lambin, E. Rios-velazquez, R. Leijenaar, S. Carvalho, R. G. Van-stiphout et al., Extracting more information from medical images using advanced feature analysis, Eur. J. Cancer, vol.48, pp.441-446, 2012.

H. J. Aerts, E. R. Velazquez, R. T. Leijenaar, C. Parmar, P. Grossmann et al., Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach, Nat. Commun, vol.5, 2014.

F. Bensch, E. L. Van-der-veen, M. N. Hooge, L. Jorritsma-smit, A. Boellaard et al., atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer, Nat. Med, vol.24, pp.1852-1858, 2018.

C. Mu, J. Huang, Y. Chen, C. Chen, and X. Zhang, High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation, Med. Oncol, vol.28, pp.682-688, 2011.

L. Chen and X. Han, Anti-PD-1/PD-L1 therapy of human cancer: Past, present, and future, J. Clin. Investig, vol.125, pp.3384-3391, 2015.

A. Krishnamurthy and A. Jimeno, Atezolizumab: A novel PD-L1 inhibitor in cancer therapy with a focus in bladder and non-small cell lung cancers, Drugs Today, vol.53, pp.217-237, 2017.

L. Fehrenbacher, A. Spira, M. Ballinger, M. Kowanetz, J. Vansteenkiste et al., Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial, Lancet, vol.387, pp.1837-1846, 2016.

H. Jadvar, R. Delgado-bolton, H. Nadel, E. Rohren, K. Zukotynski et al., Appropriate Use Criteria for 18 F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease, J. Nucl. Med, vol.58, pp.2026-2037, 2017.

E. Lopci, C. Nanni, P. Castellucci, G. C. Montini, V. Allegri et al., Imaging with non-FDG PET tracers: Outlook for current clinical applications, Insights Imaging, vol.1, pp.373-385, 2010.

A. V. Chudgar and D. A. Mankoff, Molecular Imaging and Precision Medicine in Breast Cancer, PET Clin, vol.12, pp.39-51, 2017.

R. G. Koleva-kolarova, M. J. Greuter, T. L. Feenstra, K. M. Vermeulen, E. F. De-vries et al., Molecular imaging with positron emission tomography and computed tomography (PET/CT) for selecting first-line targeted treatment in metastatic breast cancer: A cost-effectiveness study, Oncotarget, vol.9, 2018.

B. F. Kurland, L. M. Peterson, J. H. Lee, E. K. Schubert, E. R. Currin et al., Estrogen receptor binding (FES PET) and glycolytic activity (FDG PET) predict progression-free survival on endocrine therapy in patients with ER+ breast cancer, Clin. Cancer Res, vol.23, pp.407-415, 2017.

J. E. Mortimer, F. Dehdashti, B. A. Siegel, J. A. Katzenellenbogen, P. Fracasso et al., Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: Correlation with estrogen receptor status and response to systemic therapy, Clin. Cancer Res, vol.2, pp.933-939, 1996.

G. J. Liao, A. S. Clark, E. K. Schubert, and D. A. Mankoff, 18F-Fluoroestradiol PET: Current Status and Potential Future Clinical Applications, J. Nucl. Med, vol.57, pp.1269-1275, 2016.

M. Van-kruchten, A. W. Glaudemans, E. F. De-vries, R. G. Beets-tan, C. P. Schröder et al., PET Imaging of Estrogen Receptors as a Diagnostic Tool for Breast Cancer Patients Presenting with a Clinical Dilemma, J. Nucl. Med, vol.53, pp.182-190, 2012.

E. C. Dijkers, J. G. Kosterink, A. P. Rademaker, L. R. Perk, G. A. Van-dongen et al., Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging, J. Nucl. Med, vol.50, pp.974-981, 2009.

R. P. Baum, V. Prasad, C. Schuchardt, A. Orlova, A. Wennborg et al., Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In-or 68Ga-Labeled Affibody Molecules, J. Nucl. Med, vol.51, pp.892-897, 2010.

K. Tamura, H. Kurihara, K. Yonemori, H. Tsuda, J. Suzuki et al., DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer, J. Nucl. Med, vol.54, pp.1869-1875, 2013.

Y. W. Jauw, C. W. Oordt, M. D. Hoekstra, O. S. Hendrikse, N. H. Vugts et al., Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?, Front. Pharmacol, vol.7, p.35, 2016.

G. Gebhart, L. E. Lamberts, Z. Wimana, C. Garcia, P. Emonts et al., Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): The ZEPHIR trial, Ann. Oncol, vol.27, pp.619-624, 2016.

A. S. Clark, A. Demichele, and D. Mankoff, HER2 imaging in the ZEPHIR study, Ann. Oncol, vol.27, pp.555-557, 2016.

L. H. Maguire, A. R. Thomas, and A. M. Goldstein, Tumors of the neural crest: Common themes in development and cancer: Tumors of the Neural Crest, Dev. Dyn, vol.244, pp.311-322, 2015.

Z. Bar-sever, L. Biassoni, B. Shulkin, G. Kong, M. S. Hofman et al., Guidelines on nuclear medicine imaging in neuroblastoma, Eur. J. Nucl. Med. Mol. Imaging, vol.45, 2009.

A. S. Kennedy, W. A. Dezarn, P. Mcneillie, D. Coldwell, C. Nutting et al., Radioembolization for Unresectable Neuroendocrine Hepatic Metastases Using Resin 90Y-Microspheres: Early Results in 148 Patients, Am. J. Clin. Oncol, vol.31, pp.271-279, 2008.

Y. Liu, M. Lu, H. Chang, C. Lu, D. Lin et al., Diagnostic FDG and FDOPA positron emission tomography scans distinguish the genomic type and treatment outcome of neuroblastoma, Oncotarget, vol.7, pp.18774-18786, 2016.

D. L. Chan, N. Pavlakis, G. P. Schembri, E. J. Bernard, E. Hsiao et al., Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance, vol.7, pp.1149-1158, 2017.

P. Zhang, J. Yu, J. Li, L. Shen, N. Li et al., Clinical and Prognostic Value of PET/CT Imaging with Combination of 68Ga-DOTATATE and 18F-FDG in Gastroenteropancreatic Neuroendocrine Neoplasms, Contrast Media Mol. Imaging, 2018.

A. Cistaro, N. Quartuccio, F. Caobelli, A. Piccardo, R. Paratore et al., A new promising positron-emitting radiopharmaceutical for the evaluation of neuroblastoma, Nucl. Med. Rev, vol.18, pp.102-106, 2015.

D. A. Mankoff and F. Dehdashti, Imaging Tumor Phenotype: 1 Plus 1 Is More than 2, J. Nucl. Med, vol.50, pp.1567-1569, 2009.

N. Waseem, C. M. Aparici, P. L. Kunz, and N. L. Waseem, Evaluating the Role of Theranostics in Grade 3 Neuroendocrine Neoplasms, J. Nucl. Med, vol.60, pp.882-891, 2019.

S. F. Barrington, N. G. Mikhaeel, L. Kostakoglu, M. Meignan, M. Hutchings et al., Role of imaging in the staging and response assessment of lymphoma, Consensus of the International Conference on Malignant Lymphomas Imaging Working Group, vol.32, pp.3048-3058, 2014.

B. D. Cheson, S. Ansell, L. Schwartz, L. I. Gordon, R. Advani et al., Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy, Blood, vol.128, pp.2489-2496, 2016.

F. Kong, R. J. Ford, and D. J. Yang, Managing Lymphoma with Non-FDG Radiotracers: Current Clinical and Preclinical Applications, p.20, 2019.

A. K. Buck, M. Bommer, S. Stilgenbauer, M. Juweid, G. Glatting et al., Molecular Imaging of Proliferation in Malignant Lymphoma, Cancer Res, vol.66, pp.11055-11061, 2006.

J. Nuutinen, S. Leskinen, P. Lindholm, K. Söderström, K. Någren et al., Use of carbon-11 methionine positron emission tomography to assess malignancy grade and predict survival in patients with lymphomas, Eur. J. Nucl. Med, vol.25, pp.729-735, 1998.

R. Minamimoto, L. Fayad, R. Advani, J. Vose, H. Macapinlac et al., Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring, vol.280, pp.220-229, 2016.

K. Herrmann, A. K. Buck, T. Schuster, K. Abbrederis, C. Blümel et al., Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL, Oncotarget, vol.5, pp.4050-4059, 2014.

S. Chantepie, N. Hovhannisyan, S. Guillouet, J. Pelage, M. Ibazizene et al., 18F-Fludarabine PET for Lymphoma Imaging: First-in-Humans Study on DLBCL and CLL Patients, J. Nucl. Med, vol.59, pp.1380-1385, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02006592

E. Gourni, O. Demmer, M. Schottelius, C. D'alessandria, S. Schulz et al., PET of CXCR4 Expression by a 68Ga-Labeled Highly Specific Targeted Contrast Agent, J. Nucl. Med, vol.52, pp.1803-1810, 2011.

K. Herrmann, M. Schottelius, C. Lapa, T. Osl, A. Poschenrieder et al., First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu-and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra-and Extramedullary Disease, J. Nucl. Med, vol.57, pp.248-251, 2016.

E. Hindié, The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors, vol.7, pp.1159-1163, 2017.

J. E. Gains, N. J. Sebire, V. Moroz, K. Wheatley, and M. N. Gaze, Immunohistochemical evaluation of molecular radiotherapy target expression in neuroblastoma tissue, Eur. J. Nucl. Med. Mol. Imaging, vol.45, pp.402-411, 2018.

J. E. Gains, J. B. Bomanji, N. L. Fersht, T. Sullivan, D. Souza et al., 177Lu-DOTATATE Molecular Radiotherapy for Childhood Neuroblastoma, J. Nucl. Med, vol.52, pp.1041-1047, 2011.

D. Kayano and S. Kinuya, Iodine-131 Metaiodobenzylguanidine Therapy for Neuroblastoma: Reports So Far and Future Perspective, Sci. World J, pp.1-9, 2015.

H. Deubzer, P. Hundsdoerfer, J. Fuchs, V. Prasad, B. Timmermann et al., GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors, vol.229, pp.147-167, 2017.

G. Kong, M. S. Hofman, W. K. Murray, S. Wilson, P. Wood et al., Initial Experience with Gallium-68 DOTA-Octreotate PET/CT and Peptide Receptor Radionuclide Therapy for Pediatric Patients with Refractory Metastatic Neuroblastoma, J. Pediatr. Hematol, vol.38, pp.1-96, 2016.

J. Strosberg, G. El-haddad, E. Wolin, A. Hendifar, J. Yao et al., Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors, N. Engl. J. Med, vol.376, pp.125-135, 2017.

S. Navalkissoor, G. Flux, and J. Bomanji, Molecular radiotheranostics for neuroendocrine tumours, Clin. Med, vol.17, pp.462-468, 2017.

S. T. Lee, H. R. Kulkarni, A. Singh, and R. P. Baum, Theranostics of Neuroendocrine Tumors, vol.33, pp.358-366, 2017.

C. Bailly, P. Cléry, A. Faivre-chauvet, M. Bourgeois, F. Guérard et al., Immuno-PET for Clinical Theranostic Approaches, Int. J. Mol. Sci, vol.18, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01636873

D. Giesen, M. Jalving, K. L. Moek, I. C. Kok, D. J. De-groot et al., Theranostics Using Antibodies and Antibody-Related Therapeutics, J. Nucl. Med, vol.58, pp.83-90, 2017.

L. E. Lamberts, S. P. Williams, A. G. Van-scheltinga, M. N. Hooge, L. Schroder et al., Antibody Positron Emission Tomography Imaging in Anticancer Drug Development, J. Clin. Oncol, vol.33, pp.1491-1504, 2015.

F. Kraeber-bodere, C. Bailly, M. Chérel, and J. Chatal, ImmunoPET to help stratify patients for targeted therapies and to improve drug development, Eur. J. Nucl. Med. Mol. Imaging, vol.43, pp.2166-2168, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01809742

J. Sörensen, I. Velikyan, D. Sandberg, A. Wennborg, J. Feldwisch et al., Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using, vol.6, pp.262-271, 2016.

J. W. Fletcher, B. Djulbegovic, H. P. Soares, B. A. Siegel, V. J. Lowe et al., Recommendations on the Use of 18F-FDG PET in Oncology, J. Nucl. Med, vol.49, pp.480-508, 2008.

J. Czernin, M. Allen-auerbach, D. Nathanson, K. Herrmann, and . Pet/ct, Oncology: Current Status and Perspectives. Curr. Radiol. Rep, vol.1, pp.177-190, 2013.

H. Petersen, P. C. Holdgaard, P. H. Madsen, L. M. Knudsen, D. Gad et al., FDG PET/CT in cancer: Comparison of actual use with literature-based recommendations, Eur. J. Nucl. Med. Mol. Imaging, vol.43, pp.695-706, 2016.

J. A. Thie, Understanding the standardized uptake value, its methods, and implications for usage, J. Nucl. Med, vol.45, pp.1431-1434, 2004.

T. Carlier and C. Bailly, State-Of-The-Art and Recent Advances in Quantification for Therapeutic Follow-Up in Oncology Using PET. Front, vol.2, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-01817854

J. W. Keyes, SUV: Standard uptake or silly useless value?, J. Nucl. Med, vol.36, pp.1836-1839, 1995.

J. Okada, H. Oonishi, K. Yoshikawa, J. Itami, K. Uno et al., FDG-PET for predicting the prognosis of malignant lymphoma, Ann. Nucl. Med, vol.8, pp.187-191, 1994.

H. Schöder, A. Noy, M. Gönen, L. Weng, D. Green et al., Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma, J. Clin. Oncol, vol.23, pp.4643-4651, 2005.

C. Bodet-milin, F. Kraeber-bodéré, P. Moreau, L. Campion, B. Dupas et al., Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma, Haematologica, vol.93, pp.471-472, 2008.

C. Bodet-milin, C. Bailly, M. Meignan, A. Beriollo-riedinger, R. Casasnovas et al., Predictive Power of FDG-PET Parameters at Diagnosis and after Induction in Patients with Mantle Cell Lymphoma, Interim Results from the LyMa-PET Project, vol.126, p.335, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01300802

C. Bodet-milin, C. Touzeau, C. Leux, M. Sahin, A. Moreau et al., Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: A retrospective study from the GOELAMS group, Eur. J. Nucl. Med. Mol. Imaging, vol.37, pp.1633-1642, 2010.

C. Bailly, T. Carlier, C. Touzeau, N. Arlicot, F. Kraeber-bodéré et al., Interest of FDG-PET in the Management of Mantle Cell Lymphoma
URL : https://hal.archives-ouvertes.fr/inserm-02100231

C. Bailly, T. Carlier, A. Berriolo-riedinger, O. Casasnovas, E. Gyan et al., Prognostic value of FDG-PET in patients with mantle cell lymphoma: Results from the LyMa-PET Project, Haematologica, 2019.
URL : https://hal.archives-ouvertes.fr/inserm-02266351

E. Eisenhauer, P. Therasse, J. Bogaerts, L. Schwartz, D. Sargent et al., New response evaluation criteria in solid tumours: Revised RECIST guideline (Version 1.1), Eur. J. Cancer, vol.45, pp.228-247, 2009.

P. Therasse, S. G. Arbuck, E. A. Eisenhauer, J. Wanders, R. S. Kaplan et al., New Guidelines to Evaluate the Response to Treatment in Solid Tumors, J. Natl. Cancer Inst, vol.92, pp.205-216, 2000.

L. H. Schwartz, S. Litiere, E. De-vries, R. Ford, S. Gwyther et al., RECIST 1.1-Update and Clarification: From the RECIST Committee, Eur. J. Cancer, vol.62, pp.132-137, 2016.

R. L. Wahl, H. Jacene, Y. Kasamon, and M. A. Lodge, From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors, J. Nucl. Med, vol.50, pp.122-150, 2009.

M. Al-hajj, M. W. Becker, M. Wicha, I. Weissman, and M. F. Clarke, Therapeutic implications of cancer stem cells, Curr. Opin. Genet. Dev, vol.14, pp.43-47, 2004.

C. A. Huff, W. Matsui, B. D. Smith, and R. J. Jones, The paradox of response and survival in cancer therapeutics, Blood, vol.107, pp.431-434, 2006.

C. Lin, E. Itti, C. Haioun, Y. Petegnief, A. Luciani et al., Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment versus Visual Analysis, J. Nucl. Med, vol.48, pp.1626-1632, 2007.

R. L. Wahl, K. Zasadny, M. Helvie, G. D. Hutchins, B. Weber et al., Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation, J. Clin. Oncol, vol.11, pp.2101-2111, 1993.

C. Bailly, T. Carlier, B. Jamet, T. Eugene, C. Touzeau et al., Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ?SUVmax in the FDG-Avid Patients of the IMAJEM Study, Clin. Cancer Res, vol.24, pp.5219-5224, 2018.

W. Matsui, C. A. Huff, Q. Wang, M. T. Malehorn, J. Barber et al., Characterization of clonogenic multiple myeloma cells, Blood, vol.103, pp.2332-2336, 2004.

L. Rasche, S. S. Chavan, O. W. Stephens, P. H. Patel, R. Tytarenko et al., Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing, Nat. Commun, vol.8, p.268, 2017.

L. Rasche, K. M. Kortüm, M. S. Raab, and N. Weinhold, The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma, Int. J. Mol. Sci, 1248.

A. Pugachev, S. Ruan, S. Carlin, S. M. Larson, J. Campa et al., Dependence of FDG uptake on tumor microenvironment, Int. J. Radiat. Oncol, vol.62, pp.545-553, 2005.

R. J. Gillies, P. E. Kinahan, and H. Hricak, Radiomics: Images Are More than Pictures, They Are Data, Radiology, vol.278, pp.563-577, 2016.

P. Lambin, R. T. Leijenaar, T. M. Deist, J. Peerlings, E. E. De-jong et al., The bridge between medical imaging and personalized medicine, Nat. Rev. Clin. Oncol, vol.14, pp.749-762, 2017.

M. Hatt, F. Tixier, D. Visvikis, and C. Cheze-le-rest, Radiomics in PET/CT: More Than Meets the Eye?, J. Nucl. Med, vol.58, pp.365-366, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01525677

M. Hatt, F. Tixier, L. Pierce, P. E. Kinahan, C. C. Rest et al., Characterization of PET/CT images using texture analysis: The past, the present . . . any future?, Eur. J. Nucl. Med. Mol. Imaging, vol.2016, pp.1-15
URL : https://hal.archives-ouvertes.fr/hal-01330349

M. Vallières, A. Zwanenburg, B. Badic, C. Cheze-le-rest, D. Visvikis et al., Responsible Radiomics Research for Faster Clinical Translation, J. Nucl. Med, vol.59, pp.189-193, 2018.

B. Berthon, E. Spezi, P. Galavis, T. Shepherd, A. Apte et al., Toward a standard for the evaluation of PET-Auto-Segmentation methods following the recommendations of AAPM task group No. 211: Requirements and implementation, vol.44, pp.4098-4111, 2017.

A. Zwanenburg, S. Leger, M. Vallières, and S. Löck, Image biomarker standardisation initiative. arXiv 2016

F. Tixier, C. C. Le-rest, M. Hatt, N. M. Albarghach, O. Pradier et al., Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer, J. Nucl. Med, vol.52, pp.369-378, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00574272

G. J. Cook, M. Siddique, B. P. Taylor, C. Yip, S. Chicklore et al., Radiomics in PET: Principles and applications, Clin. Transl. Imaging, vol.2, pp.269-276, 2014.

J. W. Lee and S. M. Lee, Radiomics in Oncological PET/CT: Clinical Applications, Nucl. Med. Mol. Imaging, vol.52, pp.170-189, 2018.

A. Chalkidou, M. J. O'doherty, and P. K. Marsden, False Discovery Rates in PET and CT Studies with Texture Features: A Systematic Review, PLoS ONE, vol.10, 2015.

M. L. Welch, C. Mcintosh, B. Haibe-kains, M. F. Milosevic, L. Wee et al., Vulnerabilities of radiomic signature development: The need for safeguards, Radiother. Oncol, vol.130, pp.2-9, 2019.

F. Lucia, D. Visvikis, M. Vallières, M. Desseroit, O. Miranda et al., External validation of a combined PET and MRI radiomics model for prediction of recurrence in cervical cancer patients treated with chemoradiotherapy, Eur. J. Nucl. Med. Mol. Imaging, vol.46, pp.864-877, 2019.

J. Wu, T. Aguilera, D. Shultz, M. Gudur, D. L. Rubin et al., Early-Stage Non-Small Cell Lung Cancer: Quantitative Imaging Characteristics of 18F Fluorodeoxyglucose PET/CT Allow Prediction of Distant Metastasis, Radiology, vol.281, pp.270-278, 2016.

S. Carvalho, R. T. Leijenaar, E. G. Troost, J. E. Van-timmeren, C. Oberije et al., 18F-fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC)-A prospective externally validated study, PLoS ONE, vol.13, 2018.

P. Ypsilantis, M. Siddique, H. Sohn, A. Davies, G. Cook et al., Predicting Response to Neoadjuvant Chemotherapy with PET Imaging Using Convolutional Neural Networks, PLoS ONE, vol.10, 2015.

H. Arimura, M. Soufi, H. Kamezawa, K. Ninomiya, and M. Yamada, Radiomics with artificial intelligence for precision medicine in radiation therapy, J. Radiat. Res, vol.60, pp.150-157, 2019.

F. Orlhac, S. Boughdad, C. Philippe, H. Stalla-bourdillon, C. Nioche et al., A Postreconstruction Harmonization Method for Multicenter Radiomic Studies in PET, J. Nucl. Med, vol.59, pp.1321-1328, 2018.

A. Chatterjee, M. Vallieres, A. Dohan, I. R. Levesque, Y. Ueno et al., Creating Robust Predictive Radiomic Models for Data from Independent Institutions Using Normalization, IEEE Trans. Radiat. Plasma Med Sci, vol.3, pp.210-215, 2019.

T. Upadhaya, M. Vallieres, A. Chatterjee, F. Lucia, P. A. Bonaffini et al., Comparison of Radiomics Models Built Through Machine Learning in a Multicentric Context with Independent Testing: Identical Data, Similar Algorithms, Different Methodologies, IEEE Trans. Radiat. Plasma Med Sci, vol.3, pp.192-200, 2019.

L. Liu, J. Chen, P. Fieguth, G. Zhao, R. Chellappa et al., From BoW to CNN: Two Decades of Texture Representation for Texture Classification, Int. J. Comput. Vis, vol.127, pp.74-109, 2019.

M. Desseroit, D. Visvikis, F. Tixier, M. Majdoub, R. Guillevin et al., Development of a nomogram combining clinical staging with (18)F-FDG PET/CT image features in non-small-cell lung cancer stage I-III, Eur. J. Nucl. Med. Mol. Imaging, vol.43, pp.1477-1485, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01285687

S. Chan, N. Cheng, C. Hsieh, S. Ng, C. Lin et al., Multiparametric imaging using 18F-FDG PET/CT heterogeneity parameters and functional MRI techniques: Prognostic significance in patients with primary advanced oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiotherapy, Oncotarget, vol.8, pp.62606-62621, 2017.

M. Vallières, C. R. Freeman, S. R. Skamene, and I. El-naqa, A radiomics model from joint FDG-PET and MRI texture features for the prediction of lung metastases in soft-tissue sarcomas of the extremities, Phys. Med. Boil, vol.60, pp.5471-5496, 2015.

C. Bodet-milin, C. Bailly, M. Meignan, A. Berriolo-riedinger, A. Devillers et al., Prognosis value of quantitative indices derived from initial FDG PET/CT in untreated mantle cell lymphoma patients enrolled in the Lyma trial, a LYSA study. Preliminary results, J. Nucl. Med, vol.56, p.659, 2015.

T. Carlier, C. Bailly, M. Hatt, F. Kraeber-bodéré, D. Visvikis et al., Quantification of intratumor heterogeneity derived from baseline FDG PET/CT in untreated mantle cell lymphoma patients enrolled in a prospective phase III trial of the LYSA group: Preliminary results, J. Nucl. Med, vol.56, p.429, 2015.

M. E. Mayerhoefer, C. C. Riedl, A. Kumar, P. Gibbs, M. Weber et al., Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma, Eur. J. Nucl. Med. Mol. Imaging, vol.2019, pp.1-10

F. Lucia, D. Visvikis, M. Desseroit, O. Miranda, J. Malhaire et al., Prediction of outcome using pretreatment 18F-FDG PET/CT and MRI radiomics in locally advanced cervical cancer treated with chemoradiotherapy, Eur. J. Nucl. Med. Mol. Imaging, vol.45, pp.768-786, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01659241